Pfizer Pays Merck KGaA US$850 M Upfront to Compete in Immuno-Oncology

By Heather Cartwright

Pharma Deals Review: Vol 2014 Issue 12 (Table of Contents)

Published: 9 Dec-2014

DOI: 10.3833/pdr.v2014.i12.2082     ISSN: 1756-7874

Section: Licensing



In a deal that suggests that it may no longer be interested in acquiring AstraZeneca, Pfizer has agreed to pay Merck KGaA US$850 M upfront in order to co-develop and co-commercialise the German company’s anti-PD-L1 (programmed deathligand-1) antibody MSB0010718C, which is being evaluated in a Phase II trial in patients with Merkel cell carcinoma...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details